Arvinas Inc.
5 Science Park
395 Winchester Ave
New Haven
Connecticut
06511
United States
88 articles with Arvinas Inc.
-
Arvinas Reports First Quarter 2022 Financial Results and Provides Corporate Update
5/5/2022
Arvinas, Inc. today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.
-
Arvinas to Present at Bank of America Securities 2022 Healthcare Conference
5/3/2022
Arvinas, Inc. announced that management will participate in a fireside chat at the Bank of America Securities 2022 Healthcare Conference on Tuesday, May 10 at 7:00 p.m. ET /4:00 p.m. PT in Las Vegas.
-
Arvinas to Present at Upcoming Investor Conferences
3/4/2022
Arvinas, Inc. today announced that it will participate in two upcoming virtual investor conferences: Cowen & Co. 42nd Annual Health Care Conference on Monday, March 7.
-
Arvinas Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
2/28/2022
Arvinas, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update.
-
Arvinas PROTAC® Protein Degrader Bavdegalutamide (ARV-110) Continues to Demonstrate Clinical Benefit in Men with Metastatic Castration-Resistant Prostate Cancer
2/17/2022
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced completed Phase 1 and interim Phase 2 ARDENT data for bavdegalutamide (ARV-110), a novel PROTAC® degrader targeting the androgen receptor (AR).
-
Arvinas Announces New Data from Completed Phase 1 Dose Escalation and Ongoing Phase 2 ARDENT Expansion Cohort with Novel PROTAC® Degrader Bavdegalutamide (ARV-110) to be Presented at 2022 ASCO GU Meeting
2/14/2022
Arvinas, Inc. (Nasdaq: ARVN), today announced the presentation of new data showing that bavdegalutamide (also known as ARV-110), a novel PROTAC® protein degrader targeting the androgen receptor (AR), continues to provide evidence of anti-tumor activity and patient benefit in metastatic castration-resistant prostate cancer (mCRPC).
-
Arvinas to Present at Upcoming Investor Conferences - Feb 03, 2022
2/3/2022
Arvinas, Inc., a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, announced that it will participate in two upcoming virtual investor conferences.
-
Clinical Catch-Up: December 6-10
12/13/2021
There were a lot of clinical trial announcements this week, driven by the European Society for Medical Oncology annual conference. Here’s a look. -
The 2021 San Antonio Breast Cancer Symposium is meeting December 7–10 at the Henry B. Gonzalez Convention Center in San Antonio, Texas, and virtually.
-
Arvinas and Pfizer Announce PROTAC® Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer
12/10/2021
Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced an update on Phase 1 dose escalation data of ARV-471, a novel PROTAC® estrogen receptor (ER) degrader, which is being co-developed for the treatment of patients with locally advanced or metastatic ER-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer (ER+/HER2-).
-
Arvinas and Pfizer Announce Updated Phase 1 Dose Escalation Data for ARV-471 to be Presented in Spotlight Poster Session at 2021 San Antonio Breast Cancer Symposium
11/19/2021
Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) announced today that updated safety and efficacy data from the Phase 1 dose escalation trial of ARV-471 will be presented in a spotlight poster-discussion session at the 2021 San Antonio Breast Cancer Symposium (SABCS) on December 7-10, 2021.
-
Avilar Therapeutics officially joined the game with $60 million in seed financing from RA Capital Management.
-
Arvinas to Present at Stifel 2021 Virtual Healthcare Conference
11/10/2021
Arvinas, Inc., a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, announced that Sean Cassidy, Chief Financial Officer, and Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on Tuesday, November 16 at 10:40 a.m. ET.
-
Arvinas Reports Third Quarter 2021 Financial Results and Provides Corporate Update
11/3/2021
Arvinas, Inc. today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.
-
Arvinas to Participate in Upcoming Virtual Investor Conferences in September 2021
9/1/2021
Arvinas, Inc., a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, announced that it will participate in two upcoming virtual investor conferences:
-
Arvinas Reports Second Quarter 2021 Financial Results and Provides Corporate Update
8/5/2021
Arvinas, Inc., a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.
-
Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein Degrader ARV-471
7/22/2021
Arvinas, Inc. and Pfizer Inc. today announced a global collaboration to develop and commercialize ARV-471, an investigational oral PROTAC® (PROteolysis TArgeting Chimera) estrogen receptor protein degrader.
-
Arvinas Participates in Groundbreaking Ceremony for New Space Within Downtown Crossing Development in New Haven
6/7/2021
Arvinas, Inc., a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, joined state and local officials, fellow tenants, and community partners, in a groundbreaking ceremony for 101 College Street, a new 525,000-square-foot-building to be constructed as part of New Haven’s Downtown Crossing revitalization project.
-
Arvinas to Present at the 42nd Annual Goldman Sachs Global Healthcare Conference
6/3/2021
Arvinas, Inc., a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, announced that Ron Peck, M.D., Chief Medical Officer, and Sean Cassidy, Chief Financial Officer, will participate in a fireside chat at the 42nd Annual Goldman Sachs Global Healthcare Conference on Thursday, June 10 at 10:30 a.m. ET.